SCHEMBL839411

SCHEMBL839411

CCCCCCCCCCCCCCCCO[Si]1(OC)CCCCO1

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
LTA4H P09960 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3268673 0.94
SCHEMBL27598550 0.83
SCHEMBL8346765 0.78
SCHEMBL14699481 0.74 ALDH1A1 (0.34) ALDH1A1TDP1
Ammonia Solution, Strong SCHEMBL7108016 0.73
SCHEMBL3268667 0.72 ALDH1A1 (0.34) ALDH1A1TDP1
SCHEMBL6432279 0.71
SCHEMBL2472582 0.70
Heptane SCHEMBL28498778 0.70 TSHR (0.36) ALDH1A1TDP1
SCHEMBL27603050 0.70 TSHR (0.36) ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108432-A1 WATER-IN-OIL EMULSION COSMETIC KAO CORPORATION (JP) 2026-04-23 US disclosed
EP-3981382-B1 METHOD FOR PREVENTING ADHESION OF ATMOSPHERIC TOXIC SUBSTANCE KAO CORP (JP) 2026-03-04 EP disclosed
US-12394863-B2 Composite separator for lithium secondary battery and manufacturing the same G-MATERIALS CO., LTD. (KR) 2025-08-19 US disclosed
US-20250152484-A1 OIL-IN-WATER EMULSION SKIN PREPARATION FOR EXTERNAL USE KAO CORPORATION (JP) 2025-05-15 US disclosed
US-20250082592-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION, ALLEVIATION OR TREATMENT OF SARCOPENIA, CONTAINING ROR-alpha ACTIVATOR JC1-40 SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2025-03-13 US disclosed
US-20250057872-A1 INNATE IMMUNOMODULATORY EFFECT OF GINSENG BERRY POLYSACCHARIDES IN IMMUNOCOMPROMISED CONDITIONS Gangneung-Wonju National University Industry Academy Cooperation Group (KR) 2025-02-20 US disclosed
US-12226500-B2 Method for suppressing adhesion of air harmful substances KAO CORPORATION (JP) 2025-02-18 US disclosed
EP-4186516-B1 PHARMACEUTICAL COMPOSITION COMPRISING GRAPHENE QUANTUM DOTS FOR USE IN THE TREATMENT OF VIRAL DISEASES CAUSED BY ADENOVIRUS INFECTIONS BIOGRAPHENE INC (KR) 2024-12-11 EP disclosed
US-20240398692-A1 MANUFACTURING METHOD OF COFFEE CELL AND ADVENTITIOUS ROOT CULTURE COMPRISING INCREASED BIOACTIVE SUBSTANCES AND USE THEREOF BIO-FD&C (KR) 2024-12-05 US disclosed
EP-4470629-A1 OIL-IN-WATER EMULSION SKIN PREPARATION FOR EXTERNAL USE Kao Corporation (JP) 2024-12-04 EP disclosed
US-20210000884-A1 PROTEINS DERIVED FROM STREPTOCOCCUS PYOGENES BACTERIA AND USE THEREOF MD HEALTHCARE INC. (KR) 2021-01-07 US disclosed
WO-2020246556-A1 METHOD FOR SUPPRESSING ATTACHMENT OF AIR POLLUTANTS 花王株式会社 2020-12-10 WO disclosed
US-10398638-B2 Powder dispersant, and powder dispersion composition and cosmetic product containing the same SAKAMOTO YAKUHIN KOGYO CO., LTD. (JP) 2019-09-03 US disclosed
EP-3222268-A1 POWDER DISPERSANT, POWDER-DISPERSED COMPOSITION CONTAINING SAME, AND COSMETIC Sakamoto Yakuhin Kogyo Co. Ltd. (JP) 2017-09-27 EP disclosed
US-20170216187-A1 POWDER DISPERSANT, AND POWDER DISPERSION COMPOSITION AND COSMETIC PRODUCT CONTAINING THE SAME SAKAMOTO YAKUHIN KOGYO CO., LTD. (JP) 2017-08-03 US disclosed
EP-1634564-B2 Cosmetic preparation comprising a crosslinked (meth)acrylic acid ester resin powder KAO CORP (JP) 2013-06-26 EP disclosed
US-8142768-B2 Cosmetic preparation KAO CORPORATION (JP) 2012-03-27 US disclosed
EP-1634564-B1 Cosmetic preparation comprising a crosslinked (meth)acrylic acid ester resin powder KAO CORP (JP) 2010-01-06 EP disclosed
EP-1634564-A1 Cosmetic preparation comprising a crosslinked (meth)acrylic acid ester resin powder Kao Corporation (JP) 2006-03-15 EP disclosed
US-20050266057-A1 Cosmetic preparation KAO CORPORATION (JP) 2005-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250082592-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION, ALLEVIATION OR TREATMENT OF SARCOPENIA, CONTAINING ROR-alpha ACTIVATOR JC1-40 TFAM, RORA, CKMT1A; CKMT1B ALDH1A1 1743/4885TDP1 1436/4885LTA4H 4493/4885
US-20050266057-A1 Cosmetic preparation CUTA, FANCF, ASH2L ALDH1A1 1512/4885TDP1 4355/4885LTA4H 1658/4885
US-20250152484-A1 OIL-IN-WATER EMULSION SKIN PREPARATION FOR EXTERNAL USE CUTA, NAPEPLD, LIPA ALDH1A1 4738/4885TDP1 4377/4885LTA4H 599/4885
US-20260108432-A1 WATER-IN-OIL EMULSION COSMETIC FOXM1, TYR, MITF ALDH1A1 1486/4885TDP1 673/4885LTA4H 1663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.